.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Citi
Chinese Patent Office
UBS
Daiichi Sankyo
AstraZeneca
Cipla
Argus Health
Boehringer Ingelheim
Merck

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,692,763

« Back to Dashboard

Which drugs does patent 6,692,763 protect, and when does it expire?


Patent 6,692,763 protects MENOSTAR and is included in one NDA.

This patent has thirty-seven patent family members in twenty-five countries.

Summary for Patent: 6,692,763

Title: Methods for treating postmenopausal women using ultra-low doses of estrogen
Abstract:The present invention provides methods for treating physical conditions resulting from postmenopausel estrogen decline in a postmenopausel subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit for carrying out the methods of the present invention.
Inventor(s): Cummings; Steven R. (Mill Valley, CA), Ettinger; Bruce (San Francisco, CA), Ellman; Herman (Mountain Lakes, NJ)
Assignee: The Regents of the University of California (Oakland, CA) Kaiser Foundation Health Plan, Inc. (Oakland, CA) The Permanente Medical Group, Inc. (Oakland, CA) Berlex Laboratories, Inc. (Richmond, CA)
Application Number:09/554,789
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer HlthcareMENOSTARestradiolFILM, EXTENDED RELEASE;TRANSDERMAL021674-001Jun 8, 2004RXYesYes► Subscribe► SubscribeYPREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,692,763

PCT Information
PCT FiledNovember 21, 1998PCT Application Number:PCT/US98/24677
PCT Publication Date:June 03, 1999PCT Publication Number: WO99/26631

Non-Orange Book Patents for Patent: 6,692,763

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,891,868 Methods for treating postmenopausal women using ultra-low doses of estrogen► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,692,763

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2306881► Subscribe
Chile2004001852► Subscribe
China1279611► Subscribe
China100398110► Subscribe
Czech Republic20001602► Subscribe
Czech Republic299226► Subscribe
Germany69829501► Subscribe
Denmark1032398► Subscribe
Germany69839026► Subscribe
Eurasian Patent Organization200000563► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Medtronic
UBS
Argus Health
McKinsey
Colorcon
Johnson and Johnson
Accenture
Chinese Patent Office
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot